by Rod Raynovich | Sep 27, 2011 | 2023-24 Life Science Portfolios, BIOgraph
A 2.7+% rally faded today as European debt crisis headlines put a damper on optimism. Many of the pundits were skeptical of the rally saying it was driven by short covering. Biotechs Outperforming This Month With all of this volatility you’d think we found a...
by Rod Raynovich | Sep 21, 2011 | 2023-24 Life Science Portfolios, Macro
S&P Sells Off 2.94%-Caution Comes Back as Market is Down 4% in 3 Trading Days Something happened, but maybe we were just reminded that the economic picture is still grim and monetary policy has done what it can. Europe is still a time bomb with funding for Greece...
by Rod Raynovich | Sep 16, 2011 | 2023-24 Life Science Portfolios, BIOgraph, RAG
Biotechnology,Pharmaceuticals and Healthcare Providers Are Most Attractive After a five day rally led by chips, tech and industrials Morgan Stanley came out today calling the healthcare sector an overweight. Adam Parker, the US Equity Strategist published a report...
by Rod Raynovich | Sep 15, 2011 | 2023-24 Life Science Portfolios, Macro
A short term liquidity deal by the ECB to lend dollars to Euro-area banks has taken the heat off the sovereign debt crisis. For now.Many analysts however offer caution that the long term solvency issues have not been resolved. It does show that international central...
by Rod Raynovich | Sep 14, 2011 | 2023-24 Life Science Portfolios, Macro
You can’t say we didn’t warn you that traders were tired of selling. Selling was exhausted by Monday as futures were down then turned positive by mid-day Monday. The roller coaster market tied to European chit chat is too amazing. Today the focus was on...
by Rod Raynovich | Sep 12, 2011 | 2023-24 Life Science Portfolios
We are at the Rodman And Renshaw Meeting today while the market ignored macro events and found buyers in the life sciences and tech sectors. We will offer some bottom fishing ideas this week in addition to stocks mentioned last week. The trade for any upswing is long...
by Rod Raynovich | Sep 6, 2011 | 2023-24 Life Science Portfolios, 2024 Rayno Biopharmaceuticals Portfolio
A Place to Hide from Volatility Today was not as bad as early futures and European markets would portend. The S&P cut its losses to 0.74% and the NASDAQ was down only 0.26%. But as we recommended last month the healthcare sector looks good for relative safety....
by Rod Raynovich | Sep 2, 2011 | 2023-24 Life Science Portfolios, BIOgraph
On August 21 we suggested that large cap drug and biotech stocks were a good place to hide and this is the case today with the healthcare sector the least damaged on a disappointing jobs report and mortgage related litigation that will further hurt the housing...
by Rod Raynovich | Aug 31, 2011 | 2023-24 Life Science Portfolios, Macro
Worse August in a Decade Down 6%-Economic Data Still Foreboding and Macro Headwinds Remain If you were on vacation for the month of August and reviewed your “balanced” portfolio today you might wonder what everyone was freaking out about. Treasuries were...
by Rod Raynovich | Aug 29, 2011 | 2023-24 Life Science Portfolios, BIOgraph
Personalized Medicine Achieves Milestone with Lung Cancer Drug Friday’s rally picked up steam today as devastation from Hurricane Irene was less than expected and consumer spending was up. Greek stocks also rallied on a bank merger. Why are Greek stocks boosting...